Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios-Athanasios Dimopoulos

Showing results (241-250 of 283) with videos related to

Pageof 29
Sort By:
Plos Pathogens|September 22, 2021
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaquesMargherita Rosati, Mahesh Agarwal, Xintao Hu, et al.
Blood Cancer Journal|May 8, 2023
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Lancet (London, England)|June 7, 2021
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trialPhilippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 13, 2018
Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)Georgiops Tsironis, Konstantinos Koutsoukos, Konstantinos Athanasakis, et al.
Blood Cancer Journal|December 27, 2025
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCOGurdeep Parmar, Marcelo Capra, Fernanda Seguro, et al.
American Journal of Hematology|June 11, 2024
Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myelomaIoannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, Pantelis Rousakis, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaMeletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, et al.
Neuromuscular Disorders : NMD|November 6, 2021
Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the countryGeorgios Koutsis, Efstathios Kastritis, Zoi Kontogeorgiou, et al.
Cancers|August 27, 2021
Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 PatientsIoannis V Kostopoulos, Evangelos Eleutherakis-Papaiakovou, Pantelis Rousakis, et al.
Blood|April 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myelomaSarah A Holstein, Shebli Atrash, Hira Mian, et al.
Pageof 29

Showing results (241-250 of 283) with videos related to

Sort By:
Pageof 29
Plos Pathogens|September 22, 2021
Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaquesMargherita Rosati, Mahesh Agarwal, Xintao Hu, et al.
Blood Cancer Journal|May 8, 2023
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Lancet (London, England)|June 7, 2021
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trialPhilippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 13, 2018
Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)Georgiops Tsironis, Konstantinos Koutsoukos, Konstantinos Athanasakis, et al.
Blood Cancer Journal|December 27, 2025
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCOGurdeep Parmar, Marcelo Capra, Fernanda Seguro, et al.
American Journal of Hematology|June 11, 2024
Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myelomaIoannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, Pantelis Rousakis, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaMeletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, et al.
Neuromuscular Disorders : NMD|November 6, 2021
Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the countryGeorgios Koutsis, Efstathios Kastritis, Zoi Kontogeorgiou, et al.
Cancers|August 27, 2021
Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 PatientsIoannis V Kostopoulos, Evangelos Eleutherakis-Papaiakovou, Pantelis Rousakis, et al.
Blood|April 25, 2025
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myelomaSarah A Holstein, Shebli Atrash, Hira Mian, et al.
Pageof 29